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Reported is a patient with severe alopecia areata, multi-
ple autoimmune diseases (chronic lymphocytic thyroi-
dis, primary ovarian failure), and Down syndrome. She
had a poor response to topical treatment with gluco-
corticoids and minoxidil, but showed some improve-
ment with glucocorticoid injections. At the time of
evaluation, she had hair loss on 85–90% of her scalp.
She was treated initially with oral prednisone 50 mg per
day for 2 weeks, followed by a 3-month course of
prednisone 10 mg per day and cyclosporine 125 mg
(4 mg kg 1) two times per day. She responded well with
excellent regrowth of hair on the scalp, and prednisone
was tapered and ultimately discontinued. Importantly,
her parents noted marked improvement in sense of
well-being. Several months after discontinuing treat-
ment, she developed hyperpigmentation on the trunk
consistent with confluent and reticulated papillomatosis;
she has several known risk factors for this disorder, but
it is not clear if this is related to her previous treatment.
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CASE DESCRIPTION
The patient is a 13 3/12-year-old female whom I first met when
she was 11 9/12 years for chronic lymphocytic thyroiditis,
primary (presumed autoimmune) ovarian failure, and Down
syndrome. At that time, she was already on therapy for her
hypothyroidism, but she had begun to develop patchy hair loss.
She had poor response to topical treatments (glucocorticoids,
minoxidil), but showed some improvement with glucocorticoid
injections. Over the next 4 months, the hair loss worsened, and
the patches started to consolidate. Hair loss was stable for about
a year, then began to worsen again, concerning for progression
to alopecia totalis. Importantly, the hair loss was becoming a
source of distress to her. She was referred to a specialist within
dermatology; at that time she had hair loss on 85–90% of her
scalp. She began therapy with oral prednisone 50mg per day 2
weeks, followed by prednisone 10mg per day and cyclosporine
125mg (4mgkg1) two times daily. She responded over the
next 3 months with excellent regrowth of hair on the scalp, and
was noted to have improvements in sense of well-being.
Cyclosporine was discontinued, and prednisone was tapered
and ultimately discontinued. Several months after discontinuing
treatment, she developed hyperpigmentation on the trunk con-
sistent with confluent and reticulated papillomatosis.
DISCUSSION
The patient’s alopecia areata developed as part of a cluster of
autoimmune diseases including chronic lymphocytic thyroiditis
and primary ovarian failure. This is consistent with the reported
associated HLA haplotypes in alopecia areata (Petukhova et al.,
2010). The occurrence of hypothyroidism in the setting of
Down syndrome is probably incidental, as the patient has
positive thyroglobulin and TPO (thyroperoxidase) antibodies.
The response of late-stage hair loss to combined therapy with
cyclosporine and prednisone is very much of interest. Cyclo-
sporine is an immune suppressant drug, and also has the effect of
stimulating anagen phase transition in hair follicles. Despite the
anagen hair follicles being the target for immune destruction,
there apparently was a net positive effect on hair growth. Cyclo-
sporine therapy can lead to diabetes mellitus, causing insulin
resistance and b-cell damage in the pancreatic islets. Prednisone
also causes insulin resistance. Fortunately, the clinical response
of increased hair growth developed quickly, and these possible
long-term treatment complications were not a factor.
That this patient later developed confluent and reticulated
papillomatosis is unexpected. Confluent and reticulated papil-
lomatosis is a syndrome of keratinocyte hyperproliferation
of unknown cause. It can usually occurs shortly after puberty,
and has been associated with hypothyroidsm, excess weight
gain, and menstrual irregularity, all of which this patient has.
The direct effect of cyclosporine on keratinocytes is to inhibit
proliferation, and it therefore seems unlikely that the late
development of this complication was a result of this therapy.
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